4.8 Article

Hypertension

Journal

LANCET
Volume 386, Issue 9995, Pages 801-812

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(14)61468-9

Keywords

-

Funding

  1. UK National Institute for Health Research Biomedical Research Centre
  2. MRC [G9521010] Funding Source: UKRI
  3. Medical Research Council [MR/K006584/1, G9521010] Funding Source: researchfish
  4. National Institute for Health Research [NF-SI-0512-10113] Funding Source: researchfish

Ask authors/readers for more resources

Raised blood pressure is the biggest single contributor to the global burden of disease and to global mortality. The numbers of people affected and the prevalence of high blood pressure worldwide are expected to increase over the next decade. Preventive strategies are therefore urgently needed, especially in less developed countries, and management of hypertension must be optimised. Genetic advances in some rare causes of hypertension have been made lately, but the aggregate effect on blood pressure of all the genetic loci identified to date is small. Hence, intervention on key environmental determinants and effective implementation of trial-based therapies are needed. Three-drug combinations can control hypertension in about 90% of patients but only if resources allow identification of patients and drug delivery is affordable. Furthermore, assessment of optimal drug therapy for each ethnic group is needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available